



Obiltoxaximab

Revised: December 3, 2018.

CASRN: 1351337-07-9

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of obiltoxaximab during breastfeeding. Because obiltoxaximab is a large protein molecule with a molecular weight of 148,000, absorption by the infant is unlikely after the first few weeks postpartum, and it will probably be destroyed in the infant's gastrointestinal tract. Until more data become available, obiltoxaximab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Obiltoxaximab

CAS Registry Number

1351337-07-9

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal